Cited 21 times in
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박미숙 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이광훈 | - |
dc.contributor.author | 이도연 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2014-12-20T17:22:30Z | - |
dc.date.available | 2014-12-20T17:22:30Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94482 | - |
dc.description.abstract | OBJECTIVES: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection. METHODS: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls. RESULTS: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355). CONCLUSION: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 184~191 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/surgery* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intra-Arterial | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Liver Neoplasms/surgery* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/prevention & control | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Kim D.Y. | - |
dc.contributor.googleauthor | Ahn S.H. | - |
dc.contributor.googleauthor | Kim S.U. | - |
dc.contributor.googleauthor | Choi S.B. | - |
dc.contributor.googleauthor | Lee K.-H. | - |
dc.contributor.googleauthor | Park M.S. | - |
dc.contributor.googleauthor | Park J.Y. | - |
dc.contributor.googleauthor | Lee D.Y. | - |
dc.contributor.googleauthor | Han K.-H. | - |
dc.contributor.googleauthor | Kim K.S | - |
dc.identifier.doi | 10.1159/000333827 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01463 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02676 | - |
dc.contributor.localId | A02718 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 22067673 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/333827 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Adjuvant therapy | - |
dc.subject.keyword | Hepatic | - |
dc.subject.keyword | arterial infusional chemotherapy | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Mi Sook | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Kwang Hun | - |
dc.contributor.alternativeName | Lee, Do Yun | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Mi-Suk | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Kwang Hun | - |
dc.contributor.affiliatedAuthor | Lee, Do Yun | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 81 | - |
dc.citation.number | 3-4 | - |
dc.citation.startPage | 184 | - |
dc.citation.endPage | 191 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.81(3-4) : 184-191, 2011 | - |
dc.identifier.rimsid | 27359 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.